Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : Follicular patterned thyroid nodules with incomplete nuclear features of papillary thyroid carcinoma (FTN-INPTCs) are difficult to diagnose, and their biological behavior and association with follicular variants of PTC (FVPTCs) have not yet been established. The aim of this study is to determine immunohistochemical and molecular characteristics of FTNINPTCs. Methods : We investigated immunohistochemical features (galectin-3, HBME-1, CK19, fibronectin-1, CITED1), BRAF V600E mutation and RASSF1A promoter methylation status in 30 FTN-INPTC cases, along with 26 FVPTCs, 21 follicular adenomas (FAs) and 14 nodular hyperplasias (NHs). Results : Expression of galectin-3, HBME-1, CK19 and CITED1 was significantly higher in FTN-INPTCs than in FAs or NHs, but expression of galectin-3, CK19 and fibronectin-1 was lower in FTN-INPTCs than in FVPTCs. The BRAF V600E mutation was not detected in the benign nodules or FTN-INPTCs, whereas 57% of FVPTCs had the mutation. RASSF1A promoter methylation was higher in FTN-INPTCs than in benign nodules but there was no difference between FTN-INPTCs and FVPTCs. Conclusions : Our results represent the borderline immunohistochemical and molecular characteristics of FTN-INPTC. We conclude that FTN-INPTC is an intermediate lesion between a benign nodule and a FVPTC, and that it is pathogenetically related to FVPTC.
Abstract
Background : Follicular patterned thyroid nodules with incomplete nuclear features of papillary thyroid carcinoma (FTN-INPTCs) are difficult to diagnose, and their biological behavior and association with follicular variants of PTC (FVPTCs) have not yet been established. The aim of this study is to determine immunohistochemical and molecular characteristics of FTNINPTCs. Methods : We investigated immunohistochemical features (galectin-3, HBME-1, CK19, fibronectin-1, CITED1), BRAF V600E mutation and RASSF1A promoter methylation status in 30 FTN-INPTC cases, along with 26 FVPTCs, 21 follicular adenomas (FAs) and 14 nodular hyperplasias (NHs). Results : Expression of galectin-3, HBME-1, CK19 and CITED1 was significantly higher in FTN-INPTCs than in FAs or NHs, but expression of galectin-3, CK19 and fibronectin-1 was lower in FTN-INPTCs than in FVPTCs. The BRAF V600E mutation was not detected in the benign nodules or FTN-INPTCs, whereas 57% of FVPTCs had the mutation. RASSF1A promoter methylation was higher in FTN-INPTCs than in benign nodules but there was no difference between FTN-INPTCs and FVPTCs. Conclusions : Our results represent the borderline immunohistochemical and molecular characteristics of FTN-INPTC. We conclude that FTN-INPTC is an intermediate lesion between a benign nodule and a FVPTC, and that it is pathogenetically related to FVPTC.
참고문헌 (30)
- Rosai J, "Tumors of the thyroid gland. in: Atlas of tumor pathology", pp.65~121 (1992), Armed Forces Institute of Pathology
- Chan J, "Tumors of the thyroid and parathyroid glands. in: Diagnostic Histopathology of Tumors", pp.997~1081 (2007), Churchill Livingstone
- Williams ED, "Guest Editorial: two proposals regarding the termi-nology of thyroid tumors", Int J Surg Pathol, 8, pp.181~183 (2000)
- Papotti M, "Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential", Mod Pathol, 18, pp.541~546 (2005)
- Shivakumar L, "The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation", Mol Cell Biol, 22, pp.4309~4318 (2002)
- Kimura ET, "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Xing M, "Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis", Cancer Res, 64, pp.1664~1668 (2004)
- Schagdarsurengin U, "Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma", Cancer Res, 62, pp.3698~3701 (2002)
- Orlandi F, "Galectin-3 is a presurgical marker of human thyroid carcinoma", Cancer Res, 58, pp.3015~3020 (1998)
- Bartolazzi A, "Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions", Lancet, 357, pp.1644~1650 (2001)
- Sack MJ, "HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma", Mod Pathol, 10, pp.668~674 (1997)
- de Matos PS, "Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy", Histopathology, 47, pp.391~401 (2005)
- Raphael SJ, "High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors", Mod Pathol, 7, pp.295~300 (1994)
- Prasad ML, "Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18, pp.48~57 (2005)
- Herman JG, "Methylation-specific PCR:a novel PCR assay for methylation status of CpG islands", Proc Natl Acad Sci, pp.9821~9826 (1996)
- Weisenberger DJ, "Analysis of repetitive element DNA methylation by MethyLight", Nucleic Acids Res, 33, pp.6823~6836 (2005)
- Eads CA, "Epigenetic patterns in the progression of esophageal adenocarcinoma", Cancer Res, 61, pp.3410~3418 (2001)
- Hirokawa M, "Observer variation of encapsulated follicular lesions of the thyroid gland", Am J Surg Pathol, 26, pp.1508~1514 (2002)
- Berho M, "Clear nuclear changes in Hashimoto’s thyroiditis. A clinicopathologic study of 12 cases", Ann Clin Lab Sci, 25, pp.513~521 (1995)
- Fusco A, "Assessment of RET", PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer, 2002, pp.160, 2157~2167
- Arora N, "Do benign thyroid nodules have malignant potential? An evidence-based review", World J Surg, 32, pp.1237~1246 (2008)
- Okayasu I, "Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans", Cancer, 76, pp.2312~2318 (1995)
- Gasbarri A, "Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto’s thyroiditis", Br J Cancer, 91, pp.1096~1104 (2004)
- Rhoden KJ, "RET", papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma, 2006, pp.91, 2414~2423
- Young Joo Park, "Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, HighMolecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the DifferentialDiagnosis of Thyroid Nodules", Journal of Korean Medical Science, 22(4), pp.621~628 (2007), 대한의학회
- Coli A, "Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia", Histopathology, 40, pp.80~87 (2002)
- Vasko VV, "Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma", Eur J Endocrinol, 151, pp.779~786 (2004)
- Nakamura N, "RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors", Lab Invest, 85, pp.1065~1075 (2005)
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)